Navigation Links
Tumor suppressor may attenuate fibrotic disease
Date:2/17/2009

New research reveals a critical cellular signaling pathway that is responsible for generating excess connective tissue in multiple organs, similar to what is seen in human patients with scleroderma. The study, published by Cell Press in the February issue of the journal Developmental Cell, also reveals an intriguing but unexpected regulatory role for a tumor suppressor gene in fibrotic disease.

Platelet derived growth factors (PDGF) regulate the proliferation, survival, migration and differentiation of cells and play a critical role during embryonic development. However, the consequences of excess PDGF signaling are not very well understood.

"Aberrant PDGF signaling has been implicated in diverse fibrotic conditions where connective tissue cells called fibroblasts proliferate and deposit excessive connective tissue, leading to progressive scarring and organ dysfunction," says senior study author, Dr. Philippe Soriano from the Mount Sinai School of Medicine in New York."For example, human scleroderma patients, who characteristically exhibit widespread fibrosis, possess antibodies that activate PDGF receptors."

Dr. Soriano and Dr. Lorin E. Olson, who conducted this work initially at the Fred Hutchinson Cancer Research Center in Seattle and then pursued it at Mount Sinai, developed a mouse model in which they could selectively activate the PDGF receptor alpha (PDGFR?) during embryonic development and in adult animals.

The researchers found that elevated PDGFR? signaling led to aberrant overgrowth of connective tissue. In adults, this led to a progressive fibrosis in multiple organs. Interestingly, loss of the tumor suppressor Ink4a/Arf dramatically accelerated the development of fibrotic lesions. This finding suggests that cells may attenuate the effects of PDGFR? signaling through an Ink4a/Arf-dependent mechanism.

The study provides insight into the signaling pathways involved in connective tissue disease and highlights a new role for tumor-suppressors in the regulation of fibrotic conditions. "Our findings provide direct evidence that increased PDGFR? signaling can be sufficient to drive systemic connective tissue disease in organ systems that are relevant to human scleroderma," concludes Dr. Soriano. "The work also establishes an excellent animal model for testing novel therapeutic approaches for blocking aberrant PDGFR? signaling in human disease."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Estrogen found to increase growth of the most common childhood brain tumor
2. Blocking protein leads to fewer, smaller skin cancer tumors
3. Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
4. Immune Cells Shrink Tumors in Mice
5. Normalizing tumor vessels leaves cancer more benign
6. Biking for Fun, Sport, and Brain Tumor Awareness
7. Innovative method to starve tumors
8. Levels of Circulating Tumor Cells Could Predict Prostate Cancer Outcome
9. Researchers Identify Novel Mechanism That Make Cancer Tumors Grow
10. Radiofrequency treatment better than ethanol injection for small liver tumors
11. Surgical technique in Spain enables extirpation of benign tumors of the pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2017)... ... April 23, 2017 , ... ... announced the achievement of Cisco Select certification and SMB specialization. Altura is ... , In earning the Select Certification, Altura fulfilled the training and ...
(Date:4/22/2017)... ... 22, 2017 , ... The San Juan Capistrano summer camp team at the Boys ... need for summer camps to provide physical activities for all campers. To read the report, ... Camps , With an increase in specialty camps that focus on what the report terms ...
(Date:4/21/2017)... ... , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , has ... bony lump located on the forehead usually attributed to a facial fracture. Their appearance ... Dr. Shah has discovered an approach that is minimally invasive. He is an expert ...
(Date:4/21/2017)... ... 21, 2017 , ... The adage “Show, don’t tell” applies perfectly to Green ... company’s esteemed VISION House demonstration project series. Manifesting the concept of right-sized living, the ... need to live affordably and abundantly without unduly taxing the resources of our beautiful ...
(Date:4/21/2017)... ... 21, 2017 , ... The American Medical Student Association (AMSA) ... Recovery Education, from April 24 to April 28, 2017, dedicated to increasing awareness ... The mission of AWARE is to instill a compassionate, total health approach to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the pioneer ... has been awarded a very significant patent for the ... to continual care via digital health.  This landmark patent ... property and further secures Vivify,s position as the leader ... 2009, was the first company to apply consumer mobile ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
Breaking Medicine Technology: